Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.
1. An isolated IgG antibody comprising a heavy chain comprising at the C-terminus an amino acid sequence selected from the group consisting of: PGE, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, wherein said amino acid sequence inhibits proteolytic removal by a mammalian protease.
2. The antibody according to claim 1 , further comprising a light chain.
3. The antibody according to claim 1 , wherein the antibody induces complement-dependent cytotoxicity to a lesser extent compared to an antibody lacking said amino acid sequence.
4. The antibody of claim 1 , wherein the amino acid sequence at the C-terminus comprises the sequence PGE.
5. The antibody of claim 1 , wherein the amino acid sequence at the C-terminus comprises SEQ ID NO: 6.
6. The antibody of claim 1 , wherein the amino acid sequence at the C-terminus comprises SEQ ID NO: 7.
7. The antibody of claim 1 , wherein the amino acid sequence at the C-terminus comprises SEQ ID NO: 8.
8. The antibody of claim 1 , wherein, other than said amino acid sequence, the IgG antibody is an isotype selected from the group consisting of: IgG1, IgG2, IgG3, and IgG4.
9. The antibody of claim 1 , wherein the protease is selected from a protease of CHO, HEK293, PER.C6, NSO, or Sp2/0 cell origin.
10. The antibody of claim 1 , wherein the protease is a carboxypeptidase.
11. A nucleotide construct encoding an IgG heavy chain comprising at the C-terminus an amino acid sequence selected from the group consisting of: PGE, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, wherein said amino acid sequence inhibits proteolytic removal by a mammalian protease.
12. The nucleotide construct according to claim 11 , further encoding a light chain.
13. The nucleotide construct of claim 11 , wherein the amino acid sequence at the C-terminus comprises the sequence PGE.
14. The nucleotide construct of claim 11 , wherein the amino acid sequence at the C-terminus comprises SEQ ID NO: 6.
15. The nucleotide construct of claim 11 , wherein the amino acid sequence at the C-terminus comprises SEQ ID NO: 7.
16. The nucleotide construct of claim 11 , wherein the amino acid sequence at the C-terminus comprises SEQ ID NO: 8.
17. The nucleotide construct of claim 11 , wherein, other than said amino acid sequence, the IgG antibody is an isotype selected from the group consisting of: IgG1, IgG2, IgG3, and IgG4.
18. The nucleotide construct of claim 11 , wherein the protease is selected from a protease of CHO, HEK293, PER.C6, NSO, or Sp2/0 cell origin.
19. The nucleotide construct of claim 11 , wherein the protease is a carboxypeptidase.
20. A isolated recombinant host cell which produces the antibody of claim 1 , wherein the recombinant cell is genetically engineered to produce glycoproteins having human-like or human glycosylation.
21. A method for producing an IgG antibody comprising a heavy chain comprising at the C-terminus an amino acid sequence selected from the group consisting of: PGE, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, wherein said amino acid sequence inhibits proteolytic removal by a mammalian protease, the method comprising culturing the host cell according to claim 20 and recovering said antibody from the cell culture.
22. The method according to claim 21 , wherein said host cell is a CHO or HEK cell.
23. An isolated IgG antibody comprising a heavy chain comprising at the C-terminus an amino acid sequence selected from the group consisting of: PGE, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, wherein said amino acid sequence inhibits proteolytic removal by a mammalian protease, and wherein the antibody induces complement-dependent cytotoxicity to a lesser extent compared to an antibody lacking said amino acid sequence.